Table 2.
Toxicity of bevacizumab-based combinations across MPM trials
| Toxicity, grade ≥3 (%) | Bev + erlotinib | Gem + cis
|
Carbo + pem + bev | Cis + pem + bev | Cis + pem
|
||
|---|---|---|---|---|---|---|---|
| +Bev | −Bev | +Bev | −Bev | ||||
| Proteinuria | 0 | 6 | 2 | NR | NR | NR | NR |
| VTE | 8 | 17 | 9 | NR | 14a | 4 | 1 |
| Arterial thrombosis | NR | 2 | 0 | 1 | 2 | 2 | 0 |
| Bleeding | 0 | 8 | 2 | 1 | NR | 1 | 0 |
| Hypertension | NR | 23 | 9 | 3 | 6 | 23 | 0 |
| Visceral perforation | NR | 0 | 0 | 4 | NR | 0 | 0 |
| Small bowel obstruction | NR | NR | NR | NR | 2 | NR | NR |
| RPLS | NR | NR | NR | NR | 2 | NR | NR |
| Cardiovascular adverse eventsb | NR | NR | NR | NR | NR | 29 | 1 |
Notes:
a
Toxicity grade not reported;
b
cardiovascular adverse events not defined.
Abbreviations: bev, bevacizumab; carbo, carboplatin; cis, cisplatin; gem, gemcitabine; NR, not reported; pem, pemetrexed; MPM, malignant pleural mesothelioma; RPLS, reversible posterior leukoencephalopathy; VTE, venous thromboembolism.